中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.013 seconds)

    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION
    1.
    发明申请
    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION 有权

    公开(公告)号：US20210147354A1

    公开(公告)日：2021-05-20

    申请号：US16891898

    申请日：2020-06-03

    Applicant: Novartis AG

    Inventor： Hubert BORELL ,  Anne GARDIN ,  Yi JIN ,  Eric LEGANGNEUX ,  Mike UFER

    IPC: C07D205/04 ,  C12Q1/6883 ,  G01N33/50 ,  G01N33/569

    Abstract: The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of: (i) testing whether or not the patient has the poor metabolizer genotype; and (ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and (iii) if the patient does have the poor metaboliser genotype, either (a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or (b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION
    2.
    发明申请
    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION 审中-公开

    公开(公告)号：US20170320820A1

    公开(公告)日：2017-11-09

    申请号：US15605277

    申请日：2017-05-25

    Applicant: Novartis AG

    Inventor： Hubert Borell ,  Anne GARDIN ,  Yi JIN ,  Eric LEGANGNEUX ,  Mike UFER

    IPC: C07D205/04 ,  C12Q1/68 ,  G01N33/569 ,  G01N33/50

    CPC classification number: C07D205/04 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5094 ,  G01N33/56972 ,  G01N2800/52

    Abstract: The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyi-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of: (i) testing whether or not the patient has the poor metabolizer genotype; and (ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and (iii) if the patient does have the poor metaboliser genotype, either (a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or (b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION
    3.
    发明公开
    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION 审中-公开

    公开(公告)号：US20240270688A1

    公开(公告)日：2024-08-15

    申请号：US18630271

    申请日：2024-04-09

    Applicant: Novartis AG

    Inventor： Hubert BORELL ,  Anne GARDIN ,  Yi JIN ,  Eric LEGANGNEUX ,  Mike UFER

    IPC: C07D205/04 ,  C12Q1/6883 ,  G01N33/50 ,  G01N33/569

    CPC classification number: C07D205/04 ,  C12Q1/6883 ,  G01N33/5094 ,  G01N33/56972 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2800/52

    Abstract: The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:



    (i) testing whether or not the patient has the poor metabolizer genotype; and
    (ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and
    (iii) if the patient does have the poor metaboliser genotype, either

    (a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or
    (b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION
    4.
    发明申请
    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION 审中-公开

    公开(公告)号：US20190135744A1

    公开(公告)日：2019-05-09

    申请号：US16136630

    申请日：2018-09-20

    Applicant: Novartis AG

    Inventor： Hubert BORELL ,  Anne GARDIN ,  Yi JIN ,  Eric LEGANGNEUX ,  Mike UFER

    IPC: C07D205/04 ,  G01N33/50 ,  G01N33/569 ,  C12Q1/6883

    Abstract: The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of: (i) testing whether or not the patient has the poor metabolizer genotype; and (ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and (iii) if the patient does have the poor metaboliser genotype, either (a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or (b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

Patent Agency Ranking